Cases 11 - 20 of 178
AbbVie Inc. et al v. Alkem Laboratories Limited et al
as 1:2022cv01423
Plaintiff:
AbbVie Inc., AbbVie Ltd. and Neurocrine Biosciences, Inc.
Defendant:
Alkem Laboratories Limited, Hetero Labs Limited, Hetero Labs Limited Unit-V and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Zogenix, Inc. et al v. Apotex Inc. et al
as 1:2022cv01232
Plaintiff:
Zogenix, Inc. and Zogenix International Ltd.
Defendant:
Apotex Inc., Apotex Corp. and Lupin Limited
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Neurocrine Biosciences, Inc. v. Lupin Limited et al
as 1:2022cv01061
Plaintiff:
Neurocrine Biosciences, Inc.
Defendant:
Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
ZS Pharma, Inc. et al v. Lupin Limited et al
as 1:2022cv01055
Plaintiff:
ZS Pharma, Inc. and AstraZeneca Pharmaceuticals LP
Defendant:
Lupin Limited and Lupin Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Vertex Pharmaceuticals Incorporated v. Lupin Limited et al
as 1:2022cv00966
Plaintiff:
Vertex Pharmaceuticals Incorporated
Defendant:
Lupin Limited and Lupin Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Avion Pharmaceuticals, LLC et al v. Lupin Limited et al
as 1:2022cv00729
Counter Defendant:
Avion Pharmaceuticals, LLC and Albion Laboratories, Inc.
Counter Claimant:
Lupin Limited and Lupin Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Neurocrine Biosciences, Inc. v. Lupin Limited et al
as 1:2022cv00639
Plaintiff:
Neurocrine Biosciences, Inc.
Defendant:
Lupin Limited, Lupin Pharmaceuticals, Inc. and Lupin Inc.
Counter Claimant:
Lupin Atlantis Holdings S.A.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Aragon Pharmaceuticals, Inc. et al v. Lupin Limited et al
as 1:2022cv00637
Plaintiff:
Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. and Sloan Kettering Institute for Cancer Research
Defendant:
Lupin Limited and Lupin Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
ARAGON PHARMACEUTICALS, INC. et al v. LUPIN LIMITED et al
as 2:2022cv02825
Plaintiff:
ARAGON PHARMACEUTICALS, INC., JANSSEN BIOTECH, INC. and SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Defendant:
LUPIN LIMITED and LUPIN PHARMACEUTICALS, INC.
Cause Of Action: 15 U.S.C. § 1126 Patent Infringement
In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
as 1:2021md03017
In Re:
Xarelto (Rivaroxaban) ('310) Patent Litigation
Not Classified By Court:
Clerk of MDL Panel, Lupin Limited, Lupin Pharmaceuticals, Inc. and others
Counter Defendant:
Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc.
Defendant:
ScieGen Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
